Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites — PRECIOSA  

Decompensated Cirrhosis and Ascites Clinical Trial

Official title: Prevention of Mortality With Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites

Status Active, not recruiting

Clinical Trial Summary

This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20% administration versus SMT alone in subjects with decompensated cirrhosis and ascites. The study population will consist of subjects being discharged after hospitalization for acute decompensation of liver cirrhosis with ascites (or with prior history of ascites requiring diuretic therapy) with or without acute-on-chronic liver failure (ACLF) at admission or during hospitalization but without ACLF at discharge.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Ascites
• Decompensated Cirrhosis and Ascites
• Fibrosis
• Liver Cirrhosis

• NCT number: NCT03451292
• Study type: Interventional
• Source: Grifols Therapeutics LLC
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: July 24, 2018
• Completion date: May 2024